SG10201501821RA - Oral formulations and lipophilic salts of methylnaltrexone - Google Patents

Oral formulations and lipophilic salts of methylnaltrexone

Info

Publication number
SG10201501821RA
SG10201501821RA SG10201501821RA SG10201501821RA SG10201501821RA SG 10201501821R A SG10201501821R A SG 10201501821RA SG 10201501821R A SG10201501821R A SG 10201501821RA SG 10201501821R A SG10201501821R A SG 10201501821RA SG 10201501821R A SG10201501821R A SG 10201501821RA
Authority
SG
Singapore
Prior art keywords
methylnaltrexone
oral formulations
lipophilic salts
lipophilic
salts
Prior art date
Application number
SG10201501821RA
Other languages
English (en)
Inventor
Syed M Shah
Christopher Richard Diorio
Eric C Ehrnsperger
Xu Meng
Shareffi Kadum A Al
Jonathan Marc Cohen
Original Assignee
Wyeth Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=44148539&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SG10201501821R(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Wyeth Llc filed Critical Wyeth Llc
Publication of SG10201501821RA publication Critical patent/SG10201501821RA/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D489/00—Heterocyclic compounds containing 4aH-8, 9 c- Iminoethano-phenanthro [4, 5-b, c, d] furan ring systems, e.g. derivatives of [4, 5-epoxy]-morphinan of the formula:
    • C07D489/06—Heterocyclic compounds containing 4aH-8, 9 c- Iminoethano-phenanthro [4, 5-b, c, d] furan ring systems, e.g. derivatives of [4, 5-epoxy]-morphinan of the formula: with a hetero atom directly attached in position 14
    • C07D489/08—Oxygen atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/10—Laxatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Emergency Medicine (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Inorganic Chemistry (AREA)
  • Neurology (AREA)
  • Pain & Pain Management (AREA)
  • Otolaryngology (AREA)
  • Hospice & Palliative Care (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
SG10201501821RA 2010-03-11 2011-03-10 Oral formulations and lipophilic salts of methylnaltrexone SG10201501821RA (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US31301810P 2010-03-11 2010-03-11

Publications (1)

Publication Number Publication Date
SG10201501821RA true SG10201501821RA (en) 2015-05-28

Family

ID=44148539

Family Applications (3)

Application Number Title Priority Date Filing Date
SG10201501821RA SG10201501821RA (en) 2010-03-11 2011-03-10 Oral formulations and lipophilic salts of methylnaltrexone
SG2012057261A SG183133A1 (en) 2010-03-11 2011-03-10 Oral formulations and lipophilic salts of methylnaltrexone
SG10201606618PA SG10201606618PA (en) 2010-03-11 2011-03-10 Oral formulations and lipophilic salts of methylnaltrexone

Family Applications After (2)

Application Number Title Priority Date Filing Date
SG2012057261A SG183133A1 (en) 2010-03-11 2011-03-10 Oral formulations and lipophilic salts of methylnaltrexone
SG10201606618PA SG10201606618PA (en) 2010-03-11 2011-03-10 Oral formulations and lipophilic salts of methylnaltrexone

Country Status (32)

Country Link
US (8) US8524276B2 (enExample)
EP (2) EP2371357B1 (enExample)
JP (4) JP6143409B2 (enExample)
KR (2) KR101913102B1 (enExample)
CN (2) CN107308125B (enExample)
AR (1) AR080491A1 (enExample)
AU (1) AU2011224275B2 (enExample)
BR (1) BR112012022873B1 (enExample)
CA (1) CA2789798C (enExample)
CL (1) CL2012002192A1 (enExample)
CO (1) CO6630134A2 (enExample)
CR (1) CR20120476A (enExample)
EA (1) EA029096B1 (enExample)
EC (1) ECSP12012208A (enExample)
ES (1) ES2623926T3 (enExample)
GE (1) GEP201606550B (enExample)
GT (1) GT201200247A (enExample)
HU (1) HUE033133T2 (enExample)
IL (1) IL221452A (enExample)
MA (1) MA34146B1 (enExample)
MX (2) MX349145B (enExample)
MY (1) MY160727A (enExample)
NZ (3) NZ703564A (enExample)
PE (1) PE20130063A1 (enExample)
PH (1) PH12012501622A1 (enExample)
PL (2) PL2371357T3 (enExample)
SG (3) SG10201501821RA (enExample)
TN (1) TN2012000392A1 (enExample)
TW (2) TWI605814B (enExample)
UA (2) UA123856C2 (enExample)
WO (1) WO2011112816A1 (enExample)
ZA (1) ZA201808498B (enExample)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI2368553T1 (sl) 2003-04-08 2015-05-29 Progenics Pharmaceuticals, Inc. Farmacevtske formulacije, vsebujoče metilnatrekson
TWI489984B (zh) 2006-08-04 2015-07-01 Wyeth Corp 用於非經腸道傳輸化合物之配方及其用途
CA2945356C (en) 2007-03-29 2021-03-23 Progenics Pharmaceuticals, Inc. (r)-n-methylnaltrexone bromide and pharmaceutical compostitions therof useful as peripheral .mu. opioid receptor antagonist
WO2008153725A2 (en) 2007-05-25 2008-12-18 North Carolina State University Viral nanoparticle cell-targeted delivery platform
US8524276B2 (en) 2010-03-11 2013-09-03 Wyeth, Llc Oral formulations and lipophilic salts of methylnaltrexone
US8939943B2 (en) 2011-01-26 2015-01-27 Kaleo, Inc. Medicament delivery device for administration of opioid antagonists including formulations for naloxone
US8627816B2 (en) 2011-02-28 2014-01-14 Intelliject, Inc. Medicament delivery device for administration of opioid antagonists including formulations for naloxone
CN110384701A (zh) * 2011-12-19 2019-10-29 萨利克斯药品有限公司 使用甲基纳曲酮口服组合物治疗和预防阿片类诱发型便秘的方法
WO2015191686A1 (en) * 2014-06-10 2015-12-17 Salix Pharmaceuticals, Inc. Methods of administering methylnaltrexone
US10441538B2 (en) * 2014-07-08 2019-10-15 Hikma Pharmaceuticals Usa Inc. Liquid naloxone spray
JP2017519803A (ja) * 2014-07-08 2017-07-20 インシス・ファーマ・インコーポレーテッド 舌下ナロキソンスプレー
US11135155B2 (en) 2014-07-08 2021-10-05 Hikma Pharmaceuticals Usa Inc. Liquid naloxone spray
US10617686B2 (en) * 2014-07-08 2020-04-14 Hikma Pharmaceuticals Usa Inc. Liquid naloxone spray
US10722510B2 (en) * 2014-07-08 2020-07-28 Hikma Pharmaceuticals Usa Inc. Liquid naloxone spray
WO2016061531A1 (en) 2014-10-17 2016-04-21 Salix Pharmaceuticals, Inc. Use of methylnaltrexone to attenuate tumor progression
KR20210105381A (ko) * 2018-12-19 2021-08-26 프리울켐 에스.피.에이. 리팍시민 정제의 제조 방법 및 리팍시민 정제
BR112021022194A2 (pt) * 2019-05-07 2021-12-28 Bausch Health Ireland Ltd Formulações líquidas para dosagem oral de metilnaltrexona
CA3142214A1 (en) 2019-06-03 2020-12-10 Bausch Health Ireland Limited Use of methylnaltrexone and rifaximin for treatment of increased gut permeability or associated disorders
EP4142727A1 (en) 2020-05-02 2023-03-08 Bausch Health Ireland Limited Methods of reducing mortality risk in subjects suffering from an underlying disease or condition by administration of methylnaltrexone
WO2023031955A1 (en) * 2021-08-28 2023-03-09 Redasani Vijayendrakumar Virendrakumar Ji Oral pharmaceutical compositions of methylnaltrexone and salt thereof

Family Cites Families (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4176186A (en) 1978-07-28 1979-11-27 Boehringer Ingelheim Gmbh Quaternary derivatives of noroxymorphone which relieve intestinal immobility
US4719215A (en) 1986-03-07 1988-01-12 University Of Chicago Quaternary derivatives of noroxymorphone which relieve nausea and emesis
US4861781A (en) 1986-03-07 1989-08-29 The University Of Chicago Quaternary derivatives of noroxymorphone which relieve nausea and emesis
CA1297218C (en) 1986-03-14 1992-03-10 Edward David Weil Thermally stable diphosphonate-type flame retardant additive for plastics
US5102887A (en) 1989-02-17 1992-04-07 Arch Development Corporation Method for reducing emesis and nausea induced by the administration of an emesis causing agent
US5780012A (en) 1990-06-21 1998-07-14 Huland; Edith Method for reducing lung afflictions by inhalation of cytokine solutions
AU5171293A (en) 1992-10-14 1994-05-09 Regents Of The University Of Colorado, The Ion-pairing of drugs for improved efficacy and delivery
US5866154A (en) 1994-10-07 1999-02-02 The Dupont Merck Pharmaceutical Company Stabilized naloxone formulations
DE19651551C2 (de) 1996-12-11 2000-02-03 Klinge Co Chem Pharm Fab Opioidantagonisthaltige galenische Formulierung
EP0880352B1 (de) 1997-02-14 1999-11-17 Gödecke Aktiengesellschaft Stabilisierung von naloxonhydrochlorid
EP0913152B1 (de) 1997-11-03 2001-12-19 Stada Arzneimittel Ag Stabilisiertes Kombinationsarzneimittel enthaltend Naloxone und ein Opiatanalgetikum
US20030158220A1 (en) 1997-11-03 2003-08-21 Foss Joseph F. Use of methylnaltrexone and related compounds to treat chronic opioid use side effects
US6274591B1 (en) 1997-11-03 2001-08-14 Joseph F. Foss Use of methylnaltrexone and related compounds
US6559158B1 (en) 1997-11-03 2003-05-06 Ur Labs, Inc. Use of methylnaltrexone and related compounds to treat chronic opioid use side affects
US5972954A (en) 1997-11-03 1999-10-26 Arch Development Corporation Use of methylnaltrexone and related compounds
GB0100115D0 (en) 2001-01-04 2001-02-14 Alchemia Pty Ltd Delivery systems
CN1525851A (zh) * 2001-05-11 2004-09-01 ������ҩ�����޹�˾ 抗滥用阿片样物质控释剂型
EP1404323B1 (en) 2001-06-05 2009-10-28 The University of Chicago Use of methylnaltrexone to treat immune suppression
US7056500B2 (en) 2001-10-18 2006-06-06 Nektar Therapeutics Al, Corporation Polymer conjugates of opioid antagonists
JP2005511693A (ja) * 2001-11-29 2005-04-28 シェーリング　コーポレイション 回転異性体の薬学的に活性な塩の量が増加した組成物の調製のためのプロセス
AU2003220290B2 (en) 2002-03-14 2007-06-14 Euro-Celtique S.A. Naltrexone hydrochloride compositions
US20030191147A1 (en) 2002-04-09 2003-10-09 Barry Sherman Opioid antagonist compositions and dosage forms
BRPI0409128A (pt) 2003-04-08 2006-03-28 Progenics Pharm Inc uso de antagonistas de opióides periféricos, especialmente metilnaltrexona para tratar sìndrome de intestino irritável
SI2368553T1 (sl) 2003-04-08 2015-05-29 Progenics Pharmaceuticals, Inc. Farmacevtske formulacije, vsebujoče metilnatrekson
AU2004229464A1 (en) * 2003-04-08 2004-10-28 Progenics Pharmaceuticals, Inc. Combination therapy for constipation comprising a laxative and a peripheral opioid antagonist
ES2625343T3 (es) * 2003-07-15 2017-07-19 Evonik Corporation Método para la preparación de formulaciones de liberación controlada
US8946262B2 (en) 2003-12-04 2015-02-03 Adolor Corporation Methods of preventing and treating gastrointestinal dysfunction
AU2004303425C1 (en) 2003-12-19 2010-02-18 Schering Corporation Pharmaceutical compositions
BRPI0418294A (pt) * 2003-12-31 2007-05-02 Pfizer Prod Inc composições sólidas farmacêuticas estabilizadas de medicamentos de baixa solubilidade, poloxámeros e polìmeros estabilizantes
CN1294728C (zh) 2004-08-05 2007-01-10 华为技术有限公司 边缘路由器提供服务质量保证的方法及系统
JP5238255B2 (ja) 2004-09-30 2013-07-17 ベクトン・ディキンソン・アンド・カンパニー ガラス製容器内の残留物を削減又は除去するための方法及びそれにしたがって製造されたガラス製容器
US20060177380A1 (en) * 2004-11-24 2006-08-10 Acura Pharmaceuticals, Inc. Methods and compositions for deterring abuse of orally administered pharmaceutical products
AR057035A1 (es) * 2005-05-25 2007-11-14 Progenics Pharm Inc SíNTESIS DE (R)-N-METILNALTREXONA, COMPOSICIONES FARMACÉUTICAS Y USOS
TWI489984B (zh) * 2006-08-04 2015-07-01 Wyeth Corp 用於非經腸道傳輸化合物之配方及其用途
WO2008021394A2 (en) * 2006-08-15 2008-02-21 Theraquest Biosciences, Llc Pharmaceutical formulations of cannabinoids and method of use
ATE553787T1 (de) * 2006-08-16 2012-05-15 Novartis Ag Vorübergehende lichtbleichung von farbigen linsenpflegelösungen
US20080233156A1 (en) * 2006-10-11 2008-09-25 Alpharma, Inc. Pharmaceutical compositions
TW200843802A (en) 2007-02-09 2008-11-16 Drugtech Corp Compositions for improving gastrointestinal nutrient and drug absorption
CA2945356C (en) * 2007-03-29 2021-03-23 Progenics Pharmaceuticals, Inc. (r)-n-methylnaltrexone bromide and pharmaceutical compostitions therof useful as peripheral .mu. opioid receptor antagonist
PT2565195E (pt) * 2007-03-29 2015-07-28 Wyeth Llc Antagonistas e receptor opióide periférico e respectivas utilizações
JP5178064B2 (ja) * 2007-06-27 2013-04-10 富士フイルム株式会社 金属表面粗化層を有する金属層積層体及びその製造方法
BRPI0912219A2 (pt) * 2008-05-07 2015-10-06 Nektar Therapeutics método, forma de dose unitária, e, antagonista de opióide oralmente administrável que atua perifericamente.
CA2676881C (en) 2008-09-30 2017-04-25 Wyeth Peripheral opioid receptor antagonists and uses thereof
JP5525247B2 (ja) * 2009-08-04 2014-06-18 株式会社神戸製鋼所 高強度で曲げ加工性に優れた銅合金
US8524276B2 (en) 2010-03-11 2013-09-03 Wyeth, Llc Oral formulations and lipophilic salts of methylnaltrexone
TW201235609A (en) * 2010-07-13 2012-09-01 Koninkl Philips Electronics Nv Low cost mounting of LEDs in TL-retrofit tubes

Also Published As

Publication number Publication date
ES2623926T3 (es) 2017-07-12
EP3178472A1 (en) 2017-06-14
US20160206612A1 (en) 2016-07-21
GT201200247A (es) 2013-09-11
JP2019034958A (ja) 2019-03-07
US20190117646A1 (en) 2019-04-25
US20130330407A1 (en) 2013-12-12
SG183133A1 (en) 2012-09-27
NZ601595A (en) 2015-01-30
EA029096B1 (ru) 2018-02-28
CN102918039A (zh) 2013-02-06
MA34146B1 (fr) 2013-04-03
US20120070495A1 (en) 2012-03-22
AR080491A1 (es) 2012-04-11
TW201141479A (en) 2011-12-01
IL221452A0 (en) 2012-10-31
PE20130063A1 (es) 2013-02-11
NZ702826A (en) 2016-08-26
JP6429955B2 (ja) 2018-11-28
KR101913102B1 (ko) 2018-10-31
UA111717C2 (uk) 2016-06-10
US8524276B2 (en) 2013-09-03
BR112012022873A2 (pt) 2016-08-30
US20190314365A1 (en) 2019-10-17
AU2011224275B2 (en) 2015-10-01
CA2789798A1 (en) 2011-09-15
CO6630134A2 (es) 2013-03-01
BR112012022873B1 (pt) 2021-09-14
US10376505B2 (en) 2019-08-13
TW201622724A (zh) 2016-07-01
EP2371357A1 (en) 2011-10-05
EP3178472B1 (en) 2021-10-27
JP2016029054A (ja) 2016-03-03
JP6143409B2 (ja) 2017-06-07
EA201270741A1 (ru) 2013-02-28
CL2012002192A1 (es) 2012-09-28
MX349145B (es) 2017-07-14
KR101982482B1 (ko) 2019-05-27
US8956651B2 (en) 2015-02-17
US10307417B2 (en) 2019-06-04
CN107308125A (zh) 2017-11-03
UA123856C2 (uk) 2021-06-16
TWI589293B (zh) 2017-07-01
ZA201808498B (en) 2019-08-28
JP6647368B2 (ja) 2020-02-14
JP2017206553A (ja) 2017-11-24
AU2011224275A1 (en) 2012-08-23
PH12012501622A1 (en) 2012-11-05
CN102918039B (zh) 2017-06-09
US20200121673A1 (en) 2020-04-23
HUE033133T2 (en) 2017-11-28
US10507206B2 (en) 2019-12-17
PL2371357T3 (pl) 2017-09-29
EP2371357B1 (en) 2017-02-01
TN2012000392A1 (en) 2014-01-30
CR20120476A (es) 2012-11-30
ECSP12012208A (es) 2015-03-31
HK1245673A1 (zh) 2018-08-31
IL221452A (en) 2017-07-31
CN107308125B (zh) 2021-07-16
CA2789798C (en) 2020-09-22
US20190117645A1 (en) 2019-04-25
MX368805B (es) 2019-10-17
SG10201606618PA (en) 2016-09-29
JP2011190259A (ja) 2011-09-29
KR20180118260A (ko) 2018-10-30
PL3178472T3 (pl) 2022-02-14
NZ703564A (en) 2016-08-26
MX2012009125A (es) 2012-09-07
US9314461B2 (en) 2016-04-19
WO2011112816A1 (en) 2011-09-15
TWI605814B (zh) 2017-11-21
GEP201606550B (en) 2016-10-10
KR20130010900A (ko) 2013-01-29
MY160727A (en) 2017-03-15
US20140249171A1 (en) 2014-09-04

Similar Documents

Publication Publication Date Title
ZA201808498B (en) Oral formulations and lipophilic salts of methylnaltrexone
ZA201209156B (en) Therapeutic oral composition
IL222406A0 (en) Improved liposomal formulations of lipophilic compounds
EP2395975A4 (en) ORAL PHARMACEUTICAL COMPOSITION OF DUTASTERIDE
IL222919A0 (en) Alcohol - resistant oral pharmaceutical form
IL231222A0 (en) Preparations containing oxidized phospholipids
ZA201205441B (en) Dental strip for administration of oral treatment
ZA201300160B (en) Formulations including amiodarone and salts thereof and methods of their manufacture and use
SMT202100026T1 (it) Formulazione farmaceutica di loratadina per l'incapsulazione e loro combinazioni
IL223311A0 (en) Oral dosage forms of bendamustine
IL224191A (en) Compositions of vitamin d and cmc epi-14 analogues
ZA201207945B (en) Salts of dexlansoprazole and their preparation
EP2734194A4 (en) ORAL CARE FORMULATIONS
ZA201300009B (en) Oral formulation of kinase inhibitors
SI2654723T1 (sl) Trdne farmacevtske dozirna oblike, ki obsegajo tadalafil in metode za njihovo pripravo
EP2529755A4 (en) PHARMACEUTICAL COMPOSITION AND PREPARATION THEREFOR FOR ORAL ADMINISTRATION
TWM390131U (en) Improved structure of dental scaler
GB0906003D0 (en) Oral drug formulation
GB201018760D0 (en) An oral dosage form
PL390434A1 (pl) Preparat leczniczy
TWM388322U (en) Improved structure of dental handpiece
GB201001335D0 (en) Drug release formulations
GB201012047D0 (en) Pharmaceutical formulations
GB201012046D0 (en) Pharmaceutical formulations